Category: Consumer goods
Industry: Exchange Traded Fund Quick infos Headquarters: Gaithersburg, Maryland, United States Trade prices Volume: Market Cap: 486.65M Prev closed: Open: High: Low: 52 week low: 52 week high: Dividends: No Dividends Next ER: February 28, 2023 Before Market Opens
Earnings History Date EPS / Forecast Revenue / Forecast May 16, 2023 February 28, 2023 -0.43 / -0.5-110K / 29.14KNovember 10, 2022 -0.48 / -0.492K / 867.83KAugust 11, 2022 -0.42 / -0.58K / 871.5KMay 12, 2022 -0.44 / -0.5932K / 1.03MBeat! view more
Historical Data Date Price Open High Low Vol Change ER Aug 11, 2022 13.77 12.75 13.79
12.46
1.27M 7.08% Aug 10, 2022 12.86 12.42 13.29
12.19
839.35K 4.30% Aug 9, 2022 12.33 12.54 13.06
12.18
911.74K -1.67% Aug 8, 2022 12.54 12.60 13.90
12.40
1.70M 1.13% Aug 5, 2022 12.40 11.30 12.54
11.20
1.01M 5.98% Aug 4, 2022 11.70 12.01 12.27
11.62
1.20M 1.65% Aug 3, 2022 11.51 12.64 13.15
10.15
4.80M -6.95% Aug 2, 2022 12.37 11.98 12.50
11.82
434.28K 2.23% Aug 1, 2022 12.10 12.01 13.03
11.79
1.97M 0.75% Jul 29, 2022 12.01 11.93 12.07
11.72
531.91K 0.67% view more
ALT
More profiles and info about the company News
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT finance.yahoo.com Apr 4, 2023 10:40 pm Altimmune starts enrolling early-stage trial for its nasal spray COVID-19 vaccine candidate marketwatch.com Apr 4, 2023 10:42 am
Altimmune Announces Financial Results for the Year Ended December 31, 2020 and Provides a Corporate Update finance.yahoo.com Apr 4, 2023 7:00 am
Altimmune Announces Initiation of 48-week Phase 2 MOMENTUM Trial of Pemvidutide in Obesity finance.yahoo.com Apr 4, 2023 7:00 am
Insider Buying: The Altimmune, Inc. (NASDAQ:ALT) Independent Director Just Bought 6.6% More Shares finance.yahoo.com Apr 4, 2023 6:08 am
Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) finance.yahoo.com Apr 4, 2023 6:00 am
Greater Washington's scientists recount the highs and lows of researching and testing Covid-19 vaccines bizjournals.com Apr 4, 2023 5:00 am WHO to weigh adding obesity therapies to 'essential' medicines list – Reuters seekingalpha.com Mar 29, 2023 10:50 pm
Altimmune Appoints Former GSK Executive Catherine Angell Sohn, Pharm.D. to its Board of Directors finance.yahoo.com Mar 27, 2023 4:05 pm
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 7, 2023 finance.yahoo.com Mar 23, 2023 7:30 am Altimmune hits 10-month low as Goldman Sachs downgrades on weight loss data seekingalpha.com Mar 23, 2023 1:46 am Altimmune leads obesity drug developers lower after data for lead asset seekingalpha.com Mar 22, 2023 2:58 am
Altimmune Announces Positive Results from Week 24 Interim Analysis of Pemvidutide MOMENTUM Phase 2 Obesity Trial and 12-Week Phase 1b Type 2 Diabetes Safety Trial finance.yahoo.com Mar 21, 2023 7:00 am
Altimmune Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update finance.yahoo.com Feb 28, 2023 7:00 am
Altimmune to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023 finance.yahoo.com Feb 21, 2023 7:30 am
Altimmune Appoints Raymond Jordt as Chief Business Officer finance.yahoo.com Jan 4, 2023 7:30 am
Altimmune Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD) finance.yahoo.com Dec 20, 2022 7:00 am Positive news on COVID vaccines weighs against concerns over new variants marketwatch.com Dec 2, 2022 11:26 am Altimmune spikes as Goldman Sachs sees over 100% upside seekingalpha.com Dec 1, 2022 11:39 pm Are needle-free COVID vaccines our way out of the pandemic? seekingalpha.com Nov 28, 2022 1:00 am This company doesn't provide a dividend.
Key Persons Chairman : Chairperson: Mitchel B. Sayare Ph.D. CEO : Vipin K. Garg CFO : Will Brown Talk about Altimmune Inc below in comments section below. Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above. This profile is based on publicly available information and is intended to be informative in nature. Most of the datas are collected by our Data Entry and we aim to be as accurate as humanly possible.
Share it with fellow traders:
or join discussions in FB below
(
FB comments )
If you are looking for News & events, Press Release, they are available on their Investors Relations site.
Consensus BUY 88 HOLD 13 SELL 0
If you want to help pay for server cost or for improving this tool. You can send it via Paypal . More features coming soon :)
Buy on Amazon Technical analysis is a collection of techniques designed to help you make trading decisions in securities markets. Technical Analysis For Dummies helps you take a hard-headed look at what securities prices are actually doing rather than what economists or analysts say they should be doing, giving you the know-how to use that data to decide whether to buy or sell individual securities.
A simple, straightforward guide to the fundamentals of technical analysis